Multiple sclerosis.
@article{Keegan2002MultipleS,
title={Multiple sclerosis.},
author={B. Mark Keegan and John H. Noseworthy},
journal={Annual review of medicine},
year={2002},
volume={53},
pages={
285-302
}
}Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system (CNS). Diagnosis rests upon identifying typical clinical symptoms and interpreting supportive laboratory and radiological investigations. The etiology is unknown; however, strong evidence suggests that MS is an autoimmune disease directed against CNS myelin or oligodendrocytes. Genetic factors are important in the development of MS. Contributing environmental determinants (possibly including infectious agents…
Figures, Tables, and Topics from this paper
figure 12.4 
figure 18.1 
table 18.1 
figure 18.10 
figure 18.12 
figure 18.13 
figure 18.14 
table 18.3 
figure 18.38 
figure 18.39 
table 18.4 
figure 18.40 
figure 18.41 
figure 18.43 
figure 4,7 
table 4.10 
figure 4.18 
figure 4.19 
figure 4.21 
table 4.21 
figure 4.22 
figure 4.23 
table 4.4 
table 4.5 
table 4.5 
figure 4.6 
table 4.7 
table 4.8 
table 4.9
101 Citations
Neuro-immune Elements of Inflammatory Disease
- Biology
- 2014
It is reported that Transient Receptor Potential Vanilloid-1 (TRPV1), expressed in a major sensory neuron subset, controls severity and progression of experimental autoimmune encephalomyelitis (EAE) in mice and likely in primary progressive MS.
Human herpes virus antibody levels in helminth treated and placebo controlled multiple sclerosis patients
- Medicine, Biology
- 2018
A key objective of the study presented in this thesis was to assess whether EBV reactivation is a complication of helminth therapy, and evidence that Intestinal parasite (helminth) infection is protective for MS as it induces a T helper2 profile and promotes regulatory cell activity is found.
Corticosteroid-responsive torticollis as a presenting symptom of multiple sclerosis
- Medicine, PsychologyJournal of the Neurological Sciences
- 2014
Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS) as neurodegenerative diseases and their treatments: A review.
- Medicine, PsychologyCurrent topics in medicinal chemistry
- 2020
It is concluded that special efforts and input should be directed towards repurposing of older drugs and on stem cells trials and as for ALS, it is highlighted that supportive measurements and supplementary treatments remains essentially needed for ALS patients and their families.
Herpes zoster and multiple sclerosis.
- Medicine, BiologyThe Journal of infectious diseases
- 2011
The time lag for the occurrence of MS could be explained by a series of processes required by the immune systems of genetically susceptible individuals to reach a ‘‘threshold’’ and start the disease process.
Hypoperfusion of the Cerebral White Matter in Multiple Sclerosis: Possible Mechanisms and Pathophysiological Significance
- Medicine, BiologyJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
- 2008
Pathologic and imaging studies suggest that ischemic changes might be involved in the development of a subtype of focal demyelinating lesions (type III lesions), and there appears to exist a relationship between decreased white matter perfusion and cognitive dysfunction in patients with MS.
Oxysterols and multiple sclerosis: Physiopathology, evolutive biomarkers and therapeutic strategy
- Biology, MedicineThe Journal of Steroid Biochemistry and Molecular Biology
- 2021
Effect of drugs in secondary disease progression in patients with multiple sclerosis
- Medicine, BiologyMultiple sclerosis
- 2004
Investigation of the use of interferon beta for immunomodulation in patients with secondary progressive multiple sclerosis found it has the potential to significantly slow disease progression and improve quality of life for patients with SPMS.
Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series
- Medicine, PsychologyBrain sciences
- 2021
A good safety profile for eculizumab therapy in MS is described, however, the available data are not sufficient to make firm conclusions about the possible efficacy of eculIZumab as a disease-modifying therapy for MS patients.
References
Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22253788 Free article on PubMed Central
- Handb Clin Neurol. 2014;122:193-209
- 2001